Manuel Comabella Lopez Dr. Manuel Comabella earned his medical degree at the University of Barcelona, completed his neurology residency at the Neurology Department of the Hospital Universitari Vall d’Hebron (HUVH), and earned his PhD at the Universitat Autònoma de Barcelona. Since 2004, Dr. Manuel Comabella is the Head of the Clinical Neuroimmunology laboratory at the Fundació Institut de Recerca del HUVH. Since June 2008 he works as a clinical neurologist at the Department of Neurology / Neuroimmunology of the MS Centre of Catalonia (Cemcat), HUVH, Barcelona. Institutions of which they are part Main researcher Clinical Neuroimmunology Vall Hebron Institut de Recerca Responsable Laboratori Multiple Sclerosis Centre of Catalonia Email Manuel Comabella Lopez Email Institutions of which they are part Main researcher Clinical Neuroimmunology Vall Hebron Institut de Recerca Responsable Laboratori Multiple Sclerosis Centre of Catalonia Dr. Manuel Comabella earned his medical degree at the University of Barcelona, completed his neurology residency at the Neurology Department of the Hospital Universitari Vall d’Hebron (HUVH), and earned his PhD at the Universitat Autònoma de Barcelona. Since 2004, Dr. Manuel Comabella is the Head of the Clinical Neuroimmunology laboratory at the Fundació Institut de Recerca del HUVH. Since June 2008 he works as a clinical neurologist at the Department of Neurology / Neuroimmunology of the MS Centre of Catalonia (Cemcat), HUVH, Barcelona.
From 1996 to 1998, Dr. Manuel Comabella was a Research Fellow in Neuroimmunology at the Center for Neurologic Diseases, Brigham and Women´s Hospital, in Boston. In 2010 was awarded with the Ayudas Merck Serono in the multiple sclerosis research area. In 2011 was awarded by the Spanish Society of Neurology (SEN) with the Biogen Idec Prize to the best publication on demyelinating disorders. In 2013 was awarded by the SEN with the Novartis Prize to the best oral communication and the best publication on demyelinating disorders. In 2014 received the Neurological Disorders Award, scientific modality, granted by the SEN. In 2016 was awarded with the Ayudas Merck Serono in the multiple sclerosis research area. From 2018 to 2020, Dr. Manuel Comabella was a collaborator of the Biomedicine area at the Division of Coordination, Evaluation and Scientific and Technical Follow-up of the State Research Agency, Ministry of Science, Innovation and Universities. Dr. Manuel Comabella is member of the Editorial Board of Journal of Neuroimmunology and Multiple Sclerosis Journal, member of the Board of the ESNI (European School of Neuroimmunology), and member of the Strategic Group of the IMSGC (International Multiple Sclerosis Genetics Consortium). He is coauthor of 297 documents indexed in MedLine (Scopus: 12916 total citations, with h-index of 54). Dr. Manuel Comabella's research interest lies in the identification of biomarkers related with different aspects of multiple sclerosis and the development of new therapeutic strategies for the disease.
Projects ADQUISICIÓN DE UN MICROSCOPIO MULTIDIMENSIONAL WIDEFIELD EQUIPADO PARA REALIZAR EXPERIMENTOS IN VIVO, DESTINADO A LA PLATAFORMA DE MICROSCOPÍA DE LA UNIDAD DE ALTA TECNOLOGÍA (UAT) IP: Inmaculada Fuentes Camps Collaborators: Soledad Gallego Melcón, Fco Javier Santos Vicente, Gema Ariceta Iraola, Santiago Ramon y Cajal Agüeras, Marta Martínez Vicente, Anna Meseguer Navarro, Manuel Comabella Lopez, Joan Sahuquillo Barris, Miguel Segura Ginard, Simon Schwartz Navarro, Anna Rosell Novel, Meritxell Genesca Ferrer Funding agency: Ministerio Ciencia, Innovación y Universidades Funding: 177204.2 Reference: EQC2019-006309-P Duration: 01/01/2019 - 31/12/2020 Estudio de la chitinase 3-like 1 como biomarcador pronóstico de neurodegeneración y potencial diana terapéutica en esclerosis múltiple para frenar la progresión de la enfermedad IP: Manuel Comabella Lopez Collaborators: Miriam Izquierdo Sans Funding agency: Instituto de Salud Carlos III Funding: 60000 Reference: INT19/00070 Duration: 01/01/2020 - 31/12/2021 Utilidad de biomarcadores de suero y líquido cefalorraquídeo en la evaluación del pronóstico y respuesta a tratamiento en pacientes con fases iniciales de Esclerosis Multiple IP: Manuel Comabella Lopez Collaborators: Alvaro Cobo Calvo, Miriam Izquierdo Sans Funding agency: Instituto de Salud Carlos III Funding: 180000 Reference: JR19/00007 Duration: 01/01/2020 - 31/12/2023 Estudio de la chitinase 3-like 1 biomarcador pronóstico de neurodegeneración y potencial diana terapéutica en esclerosis múltiple para frenar la progresión de la enfermedad. IP: Manuel Comabella Lopez Collaborators: - Funding agency: Instituto de Salud Carlos III Funding: 117370 Reference: PI18/01014 Duration: 01/01/2019 - 30/06/2023 Pagination First page « Previous page ‹ … Page 2 Page 3 Current page 4 Page 5 Page 6 … Next page › Last page »
